Buy Now

About G-NiiB

G-NiiB® is the registered trademark of GenieBiome Limited

GenieBiome Limited, a biotechnology spinout from The Chinese University of Hong Kong (CUHK) was founded by world-renowned clinician-scientists and supported by a multidisciplinary team of experts in microbiology, metagenomics, bioinformatics, disease biomarkers, food technology, clinical trials, IP development and commercialization. For over a decade, our team has pioneered the use of microbiome with evidence-based science to tackle a myriad of diseases, including novel virus, gut serious illness, overweight and metabolic syndrome, skin irritation and mental health. Our precision portfolio of G-NiiB includes diagnostic and risk prediction tests, next-generation microbiome precision formula, and precision medicine tailored for the Asian population.

We use our unique metagenomics database to identify novel microbes as diagnostic tools and generate personalized therapy for conditions with unmet needs (Microbiome Precision), and offer tailor-made microbial replacement therapy to restore imbalance in gut microbes to improve health outcomes and prevent diseases.

We pursue infinite innovations that are beyond our imagination, and to achieve impossible missions. G-NiiB is building the world's largest microBiome Asian Big data to fulfil our mission to provide evidence based targeted solutions for the health of the Next Generations.

To be the world leader in Asian Microbiota research, G-NiiB's vision is to:

  • Build the largest microbial dataset in Asia.
  • Develop microbiome-based diagnostics and therapeutics solutions.
  • Offer precise, reliable, safe and effective solutions to improve health outcomes.

Big data analysis on our exclusive and extensive database reveals that Asian and Chinese populations have unique microbiome profiles compared to other ethnicities due to hereditary and environmental factors. As such, the microbiome based application in precision diagnosis and therapy may also be different.

Informed by scientific evidence, G-NiiB aims to broaden the availability of microbiome technologies to naturally restore and improve Asian Chinese health in the most precise manner. To achieve this mission, the research team is building the world’s largest microbiome database on Chinese and Asian populations, and incorporating proprietary big data and machine learning analytics to microbiome research to improve accuracy and efficiency.

Medical Advisors

Prof Ailsa Hart

  • Consultant Gastroenterologist
  • Sub-Dean (St Mark's Academic Institute)
  • Professor of Practice, Department of Metabolism (Digestion and Reproduction), Faculty of Medicine, Imperial College London

Prof Mark Morrison

  • Chair, Microbial Biology and Metagenomics, The University of Queensland Diamantina Institute

Prof Suzanne Devkota

  • Director, Microbiome Research, Inflammatory Bowel & Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA

Prof Simon Ng

  • Professor, Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Faculty of Medicine, The Chinese University of Hong Kong

Prof Martin Wong

  • Professor (Clinical), JC School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong

Prof Mandy Sea

  • Adjunct Associate Professor, Hong Kong Institute of Diabetes and Obesity, Faculty of Medicine, The Chinese University of Hong Kong
  • Director, Dr Sea Health and Nutrition Center

Dr Stephen Cheung

  • Honorary Clinical Lecturer, Faculty of Medicine, The Chinese University of Hong Kong
  • Private Practitioner

Dr Brian Wu

  • Visiting Professor of Medicine, The General Hospital of People's Liberation Army (301 Hospital), Beijing, China
  • Private Practitioner
  • Specialty: Gastroenterology & Hepatology